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RESEARCH
Epigenome-wide association study identifies 
DNA methylation markers for asthma remission 
in whole blood and nasal epithelium
Cancan Qi1,2 , Judith M. Vonk2,3, Diana A. van der Plaat2,3, Maartje A. E. Nieuwenhuis2, F. Nicole Dijk1,2, BIOS 
Consortium, Dylan Aïssi4, Valérie Siroux4, H. Marike Boezen2,3, Cheng‑jian Xu5,6,7 and Gerard H. Koppelman1,2*
Abstract 
Background: Asthma is a chronic respiratory disease which is not curable, yet some patients experience spontane‑
ous remission. We hypothesized that epigenetic mechanisms may be involved in asthma remission.
Methods: Clinical remission (ClinR) was defined as the absence of asthma symptoms and medication for at least 
12 months, and complete remission (ComR) was defined as ClinR with normal lung function and absence of airway 
hyperresponsiveness. We analyzed differential DNA methylation of ClinR and ComR comparing to persistent asthma 
(PersA) in whole blood samples (n = 72) and nasal brushing samples (n = 97) in a longitudinal cohort of well char‑
acterized asthma patients. Significant findings of whole blood DNA methylation were tested for replication in two 
independent cohorts, Lifelines and Epidemiological study on the Genetics and Environment of Asthma (EGEA).
Results: We identified differentially methylated CpG sites associated with ClinR (7 CpG sites) and ComR (129 CpG 
sites) in whole blood. One CpG (cg13378519, Chr1) associated with ClinR was replicated and annotated to PEX11 (Per‑
oxisomal Biogenesis Factor 11 Beta). The whole blood DNA methylation levels of this CpG were also different between 
ClinR and healthy subjects. One ComR‑associated CpG (cg24788483, Chr10) that annotated to TCF7L2 (Transcription 
Factor 7 Like 2) was replicated and associated with expression of TCF7L2 gene. One out of seven ClinR‑associated CpG 
sites and 8 out of 129 ComR‑associated CpG sites identified from whole blood samples showed nominal significance 
(P < 0.05) and the same direction of effect in nasal brushes.
Conclusion: We identified DNA methylation markers possibly associated with clinical and complete asthma remis‑
sion in nasal brushes and whole blood, and two CpG sites identified from whole blood can be replicated in independ‑
ent cohorts and may play a role in peroxisome proliferation and Wnt signaling pathway.
Keywords: Asthma remission, DNA methylation, Whole blood, Nasal brushes
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Introduction
Asthma is a chronic airway disorder that affects more 
than 300 million people around the world. Asthma can-
not be completely cured with the available treatment up 
to now. However, some asthma patients may grow out of 
this disease, which is called asthma remission.
Asthma remission is more common in patients with 
childhood onset asthma, and the proportions of remis-
sion differ in different age groups at follow-up (33–53% 
in adolescence, 6–33% in young adulthood and 11–52% 
in adulthood) [1, 2]. There are two types of asthma remis-
sion, one is defined by absence of asthma symptoms and 
medication for at least one year, which is called “clinical 
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airway hyperresponsiveness (AHR) or a low lung func-
tion. Therefore, “complete remission” (ComR) was put 
forward [3]. In addition to criteria of ClinR, ComR has 
to meet additional criteria of normal lung function and 
absence of AHR. This is a more rare phenomenon, that 
takes place in 5–22% of asthmatics [2].
Asthma remission is associated with both genetic and 
environmental factors. Environmental factors includ-
ing breast feeding and having pets in childhood were 
reported to be positively associated with asthma remis-
sion [4]. A recent genome-wide association study 
(GWAS) identified one SNP (single nucleotide polymor-
phism) that was associated with ClinR and three SNPs 
with ComR. One of these SNPs was also associated with 
expression of known asthma genes including ILRL1 and 
IL13 in lung tissue [5].
Epigenetic mechanisms such as DNA methylation may 
help to build a link between genetic factors and the envi-
ronment. DNA methylation can be regulated by SNPs, 
and can reflect environmental exposures, ageing, cell type 
constitution and activation [6]. DNA methylation refers 
to the addition of a methyl-group to cytosine, which usu-
ally happens when a cytosine is located next to a guanine 
in the 5′ to 3′ direction (CpG site), and this may relate to 
the regulation of gene expression [7]. Epigenome-wide 
association studies (EWAS) have provided insights into 
the development of asthma and its remission. CpG sites 
associated with asthma in both blood and nasal epithe-
lial cells have been identified, such as CpG sites located in 
DICER1, STX3, and LIPIN1 in blood cells, and CDHR3, 
FBXL7 and NTRK1 in nasal epithelial cells [8, 9]. Ver-
meulen et  al. [10] identified 4 CpG sites and 42 regions 
that were differentially methylated between remission 
and persistent asthma (PersA) in bronchial biopsies, and 
top CpG sites were annotated to genes including ACKR2 
and DGKQ by gene expression.
Although this latter paper provided a proof of con-
cept of the relation between asthma remission and DNA 
methylation, bronchial biopsies are not easy to obtain 
for further studies. DNA methylation in whole blood 
and nasal epithelium is a good proxy for bronchial epi-
thelium and can therefore also help to understand the 
mechanism of asthma remission. Here, we hypothesize 
that epigenetic mechanisms may be involved in asthma 
remission, reflected in different DNA methylation pat-
terns in whole blood and nasal epithelium. To test this 
hypothesis, we performed an EWAS of whole blood and 
nasal DNA in subjects with PersA, ClinR and ComR. 
We investigated a longitudinal cohort in which asthma 
was initially carefully defined and the remission status 
was assessed during follow-up (median 39  years). We 
subsequently replicated the whole blood DNA results 
in two independent cohorts, and also verified the top 
results from whole blood DNA in cells obtained by nasal 
brushing.
Methods
A full description of methods is provided in the online 
supplement.
Study populations
Subjects included in this study were from long-term 
follow-up studies in the University Medical Center Gro-
ningen (UMCG). This study consists of two sources of 
subjects, (1) subjects from the third visit (2013–2014) of 
a longitudinal study described previously by Carpaij et al 
[4], and (2) additional asthma remission subjects that 
were followed up from previous genetic studies [11] and 
were re-invited in 2013–2014 to take nasal brushes and 
blood samples, during which the remission status was 
assessed again. The participants included in this cohort 
were different from those of the cohort described by Ver-
meulen et  al. [10] from our research institute. All par-
ticipants were diagnosed with asthma at baseline with 
a doctor diagnosis of asthma and AHR. Then, subjects 
had at least one follow-up medical examination dur-
ing adulthood in which their asthma status was evalu-
ated by questionnaires and in most subjects additionally 
with spirometry and an AHR test [5]. The medical ethical 
board of the UMCG approved the studies and all partici-
pants gave written informed consent.
We replicated findings in whole blood in two independ-
ent cohorts: the Lifelines population-based cohort in The 
Netherlands (where we could replicate our results on 
ClinR using Illumina 450 K array) and the Epidemiologi-
cal study on the Genetics and Environment of Asthma 
(EGEA) cohort in France, a case control and family 
study on asthma, where we could replicate our results on 
ClinR and ComR with methylC-capture sequencing [12]. 
No cohort was available to replicate our nasal findings. 
Extensive information on these cohorts is described in 
the Additional file 1.
Phenotype definition
The presence of PersA, ClinR and ComR was determined 
at the most recent visit. ClinR was defined according to 
the following criteria: (1) No use of any asthma medi-
cation, and (2) no symptoms (asthma attacks and/ or 
wheezing) in the past year. ComR was defined as ClinR 
combined with (3) no AHR  (PC20 (provocative concen-
tration causing a 20% fall in  FEV1 (forced expiratory 
volume in 1 s)) methacholine ⩽ 39.3 mg mL−1)), and (4) 
 FEV1% predicted pre-bronchodilator > 80%. PersA was 
defined as the presence of asthma symptom and/or the 
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use of asthma medication. Detailed phenotype defini-
tions of the replication cohorts are described in the Addi-
tional file 1.
DNA methylation measurements and statistical analyses
DNA was extracted from 72 whole blood and 103 nasal 
brushing samples taken at the most recent visit. Genome-
wide DNA methylation was determined using Illumina 
Infinium HumanMethylation450 BeadChips. After qual-
ity control, 72 whole blood samples and 97 nasal epi-
thelium samples (of in total 103 unique subjects) with 
436,824 CpG sites remained for following steps.
We used robust linear regression to determine the 
differential methylation between persistent asthma 
and asthma remission: (1) PersA versus ClinR, and (2) 
PersA versus ComR, in whole blood and nasal brush-
ing samples, with adjustment for covariates that are 
known to affect DNA methylation (age, sex, smoking 
status, pack years, and batch). For whole blood samples, 
we performed adjustment on the percentage of mono-
cytes, B cells, NK cells, CD4 + T cells, CD8 + T cells, 
and granulocytes, which were predicted by the House-
man [13] algorithm using minfi [14] package. For nasal 
brushing samples, we applied the R package sva [15] to 
estimate significant surrogate variables (SVs), represent-
ing unknown latent factors that capture heterogeneity 
in data, such as cell type composition. One SV for each 
analysis (ClinR and ComR) was generated and added to 
the model respectively. Differentially methylated regions 
(DMR) were identified using comb-p v0.48 [16] and 
DMRcate [17].
Replication and meta‑analyses
Genome-wide significant CpG sites that passed Bonfer-
roni correction (P < 1.14 × 10–7, which is 0.05 / 436,824) 
in whole blood DNA were selected for replication in two 
independent cohorts, Lifelines and EGEA. Lifelines did 
not include an assessment of AHR, so only included a 
ClinR phenotype available for replication. The weighted 
Z-score method was used to meta-analyze the results 
of discovery and replication cohorts, considering EGEA 
used methylC-capture sequencing method, which was 
different from discovery and Lifelines (450  K array), to 
investigate DNA methylation. CpG sites that passed the 
epigenome-wide significance threshold of P < 1.14 × 10–7 
(Bonferroni correction) in the meta-analysis of all studies 
were considered to be replicated. Finally, top sites identi-
fied in whole blood were verified in nasal brushes.
Annotation and functional relevance
Significant CpG sites were annotated by GREAT v3.0.0 
[18]. We correlated the significant CpG sites we identi-
fied to the expression level of gene nearby (with a region 
of ± 250  kb) by cis expression quantitative trait DNA 
methylation (cis-eQTM) analysis. Blood eQTM was 
assessed in the BIOS consortium dataset [19]. Matched 
nasal RNA sequencing data and DNA methylation data 
was used to perform eQTM analysis for significant nasal 
CpG sites and these results were additionally replicated 
in the larger collection of nasal brushes obtained in the 
PIAMA study [20]. The genes that were identified in 
eQTM analysis were used for pathway analysis by Con-
sensusPathDB [21]. To check if the results of replicated 
CpG sites were affected by inhaled corticosteroids (ICS), 
we stratified asthma subjects by ICS usage, and compared 
the DNA-methylation in the remission group to asthma 
with ICS and asthma without ICS group, respectively, by 
t-test. To evaluate the impact of BMI and allergic rhinitis 
on the results, we performed sensitivity analyses on the 
replicated blood CpG sites by additionally adjusting for 
allergic rhinitis and BMI respectively. We also performed 
sensitivity analysis for all significant nasal CpG sites.
Results
Subject characteristics
Subject characteristics of the discovery and replication 
cohorts are shown in Table  1. Regarding the discovery 
cohort, the median [range] duration of follow-up of the 
entire population was 39 [4–49] years. Most of the sub-
jects (group 1, n = 76) were from the study described by 
Carpaij et al. [4] at the third visit; the remaining (group 
2, n = 27) were remission subjects added to this study 
to further enrich remission cases. Characteristics of 
subjects from the two groups are shown in Additional 
file 2: Table S1. By definition, group 2 had a higher pro-
portion of remission subjects, and showed better lung 
function. Of the 103 subjects included in this study, 54 
(52.4% of total subjects) had ClinR, and 20 of the ClinR 
subjects had ComR (19.4% of total subjects). At baseline, 
subjects in remission later had higher  FEV1 and FVC 
level compared to PersA, but no difference regarding 
FEV1%predicted and FVC %predicted values was iden-
tified among the groups (Additional file  3: Figure S1). 
Within the whole dataset, 72 subjects (44 PersA, 28 ClinR 
and 10 of ClinR subjects are ComR) had whole blood 
methylation data and 97 (44 PersA, 53 ClinR and 19 of 
ClinR subjects are ComR) had nasal methylation data, 
with 66 subjects providing both (Fig. 1). White blood cell 
composition was estimated, and we did not observe sig-
nificant cell composition differences among PersA, ClinR 
and ComR group in six cell types. (Additional file 3: Fig-
ure S2).
Differential methylation in the discovery cohort of ClinR
Whole blood DNA methylation levels at seven individual 
CpG sites and 19 differentially methylated regions (DMR) 
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were significantly associated with ClinR (Fig. 2a, Table 2, 
Additional file  2: Table  S2). The Q-Q plot (Additional 
file 3: Figure S3a) and the inflation factor λ of 1.064 indi-
cated no obvious inflation of the results. Three out of the 
seven CpG sites were significantly correlated with gene-
expression level in cis (FDR < 0.05), resulting in four CpG-
gene pairs that showed negative correlation (Additional 
file 2: Table S3). These four eQTM genes were enriched in 
two pathways: G Protein Signaling Pathways and Hemo-
stasis (P < 0.01, Additional file 2: Table S4).
We also identified four epigenome-wide significant 
CpG sites and 24 DMRs that associated with ClinR 
in nasal brushes (Table  S5-S6). The Q-Q plot (Addi-
tional file  3: Figure S4a) and the λ of 1.125 indicated 
Table 1 Characteristics of study participants in the discovery and replication cohorts
Continuous data are presented as median (25th percentile; 75th percentile), category data are presented as number (percentage)
Italic values represent significant differences compared with persistent asthma with P < 0.05 in the discovery cohort
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 Male, n (%) 31 (63.3%) 37 (68.5%) 15 (75.0%) 58 (58.6%) 10 (40.0%) 384 (60.4%) 49 (46.7%) 7 (46.7%) 1 (33.3%)
 Duration of 
follow‑up, 
years









4 (8.2%) 8 (14.8%) 2 (10.0%) 27 (27.3%) 14 (56.0%) 207 (32.5%) 10 (9.5%) 2 (13.3%) 1 (33.3%)
 Ex‑smoking, 
n (%)




32 (65.3%) 28 (51.9%) 11 (55.0%) 72 (72.7%) 11 (44.0%) 429 (67.5%) 60 (57.1%) 8 (53.3%) 2 (66.7%)




33 (67.3%) 30 (55.6%) 9 (45.0%) 59 (59.6%) 13 (52.0%) 123 (19.3%) 70 (67.3%) 11 (73.3%) 2 (66.7%)




























































































































age 16, n 
(%)
48 (98.0%) 50 (92.6%) 19 (95.0%) 59 (62.1%) 18 (81.8%) 52 (49.5%) 8 (53.3%) 2 (66.7%)
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no obvious inflation of the results. We verified the 
CpG sites identified from whole blood samples in 
nasal brushes, and found that one CpG (cg15404785) 
associated with ClinR showed nominal significance 
(P < 0.05) and the same direction of effect in nasal 
brushes (Table  S7). Four ClinR-associated CpG sites 
were correlated to expression level of four genes in cis 
(nominal significant P < 0.05) in nasal brushes, with one 
pair (cg07673230-RPL30 (Ribosomal Protein L30)) also 
being nominal significant and in the same direction in 
the PIAMA dataset (Additional file 2: Table S8).
N=31       N= 66        N=6














21 candidate CpG sites
PersA vs ClinR
4 candidate CpG sites
PersA vs ComR
129 candidate CpG sites
PersA vs ClinR
7 candidate CpG sites
Annotation and functional relevance Replication in EGEA Replication in EGEA and Lifelines





Annotation and functional relevance
Meta-analysis Meta-analysis
Fig. 1 Study design. In the discovery panel,103 samples were assessed in this study, 72 subjects had whole blood DNA methylation data, 97 
subjects had nasal DNA methylation data and 66 subjects have both. Epigenome‑wide association studies were performed on clinical remission 
(ClinR) and complete remission (ComR) respectively in both whole blood and nasal samples. Significant CpG sites identified from whole blood were 
further replicated in two independent cohorts. Results of ComR were replicated in EGEA study (93 out of 129 probes available in EGEA); results of 
ClinR were replicated in EGEA study (4 out 7 probes available) and Lifelines (all 7 probes available)
Fig. 2 Manhattan plot of association between clinical remission (a)/ complete remission (b) and DNA methylation in whole blood in discovery 
cohort. In total, 436,824 CpGs were tested. The red line represents the genome‑wide significance threshold (Bonferroni correction, P < 1.14 × 10–7). 
Highlighted sites represent replicate CpG sites































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Page 8 of 13Qi et al. Clin Transl Allergy           (2020) 10:60 
Differential methylation in the discovery cohort of ComR
We identified 129 individual CpG sites and 53 regions 
that were significantly associated with ComR in whole 
blood DNA (Fig. 2b, Table 3, Additional file 2: Table S9, 
10). Q-Q plot is shown in Additional file  3: Figure S3b 
and λ was 1.178. The eQTM analysis identified 99 CpG-
gene pairs for 45 out of the 129 CpG sites (FDR < 0.05, 
Additional file  2: Table  S3). These eQTM genes were 
enriched in eight pathways (P < 0.01, Additional file  2: 
Table S4), and the top pathways were Activation of SMO 
(Smoothen), Platelet Adhesion to exposed collagen, and 
Cilium Assembly.
In nasal brushes, we identified 21 CpG sites and 62 
DMRs that were associated with ComR (Additional file 2: 
Table S11, 12). Q-Q plot is shown in Additional file 3: Fig-
ure S4b and λ was 1.318. Eight of the ComR-associated 
CpG sites identified from whole blood also showed nomi-
nal significance in nasal brushes with the same direction 
of effect (Additional file  2: Table  S13). Seven ComR-
associated CpG sites were correlated to expression level 
of nine genes in cis (nominal significant P < 0.05) in nasal 
brushes, and four pairs also showed nominal significant 
and in the same direction in PIAMA dataset (Additional 
file 2: Table S8).
Replication study
We replicated the top findings in whole blood in two 
independent cohorts. In replication cohort EGEA, four 
ClinR-associated CpG sites and 93 ComR-associated 
CpG sites were available, with one CpG site for ClinR and 
one for ComR showing nominal significance (P < 0.05) 
and the same direction as the discovery cohort. In the 
replication cohort Lifelines, which only had the ClinR 
phenotype, seven ClinR-associated CpG sites were all 
available with one CpG with P < 0.05 and the same direc-
tion. After meta-analysis, one CpG associated with ClinR 
and another one CpG associated with ComR were rep-
licated (meta P < 1.14 × 10–7). The ClinR-associated CpG 
(cg13378519) was located on Chr 1 and close to gene 
PEX11B (Peroxisomal Biogenesis Factor 11 Beta). The 
CpG site was not available in the EGEA study and was 
only replicated in Lifelines. This CpG was lower meth-
ylated in ClinR subjects compared to PersA (Fig.  3a). A 
similar trend was also found in nasal brushes although 
the association was not statistically significant (Fig.  3b). 
The methylation levels at this CpG also differed between 
ClinR and healthy subjects in Lifelines cohort (Fig.  3c), 
indicating that DNA methylation status of asthma remis-
sion subjects is not equal to that of healthy subjects. 
The ComR-associated CpG (cg24788483) was located 
on chr10 and close to gene HABP2 (Hyaluronan Bind-
ing Protein 2) and TCF7L2 (Transcription Factor 7 Like 
2). This CpG was lower methylated in ComR subjects 
compared to PersA in whole blood, but showed no obvi-
ous difference in nasal brushes (Additional file 3: Figure 
S5). In whole blood cis-eQTM analysis, this CpG was sig-
nificantly negatively correlated to the expression level of 
TCF7L2 gene (P = 9.12 × 10–7).
To evaluate potential SNP effects within the probe for 
the two replicated CpG sites, the β value distributions 
were visually assessed in the discovery cohorts (Addi-
tional file 3: Figure S6), and no bimodal distribution was 
detected indicating no underlying SNP effect within the 
probe. The regional co-methylation plots of genes anno-
tated to replicated CpG sites are shown in the Additional 
file 3: Figure S7, which showed that cg13378519 is located 
in the promoter region of PEX11B gene, and cg24788483 
is located in heterochromatin region of TCF7L2 gene. 
We did not identify any SNP that was associated with the 
two CpG sites using an online database [19].
We verified if the results of the two replicated CpG 
sites were affected by inhaled corticosteroids (ICS), 
known to affect DNA methylation at multiple sites in 
the genome (Additional file  3: Figure S8). The boxplots 
showed that the methylation levels in the remission 
groups (both ClinR and ComR) were significantly lower 
than both persistent asthma with ICS usage group and 
persistent asthma without ICS usage group, which indi-
cated that the results were not affected by the use of ICS. 
We evaluated the impact of rhinitis on our results, as 
rhinitis shows comorbidity with asthma. The replicated 
ClinR-associated CpG site showed similar effect size and 
P value before and after adjusting for rhinitis, while the 
ComR-associated CpG showed similar effect size yet the 
P value changed from 4.62E-10 to 4.07E-05 after correc-
tion for rhinitis (Additional file 2: Table S14). Additional 
adjustment for BMI did not change the results of the 
two replicated CpG sites, indicating that BMI was not a 
confounder (Additional file 2: Table S14). The significant 
CpG sites identified from nasal samples showed similar 
effect size and P value before and after adjusting for BMI 
and for rhinitis (Additional file 2: Table S15).
We also compared our results from the discovery 
cohort with the published DNA methylation study of 
asthma remission in bronchial biopsies (Vermeulen et al. 
[10]). One CpG (cg13525448), located close to LBX1 
(Ladybird Homeobox  1) gene and TLX1 (T Cell Leuke-
mia Homeobox 1) gene, in their top list of remission vs 
persistent asthma reached nominal significance (P < 0.05) 
and showed the same direction of effect in our results of 
ComR in whole blood (Additional file 2: Table S16). Two 
genes of their DMRs associated with ClinR, at the gene 
PTCHD3 (patched domain-containing protein 3) and 
LOC100507389, were also present in our results of DMRs 
associated with ClinR in nasal brushes (Additional file 2: 
Table S6).
Page 9 of 13Qi et al. Clin Transl Allergy           (2020) 10:60  
Discussion
In this study, we identified one CpG site associated with 
ClinR and a different CpG site associated with ComR 
from whole blood, that were replicated in independent 
cohorts. We also revealed that 25 CpG sites were associ-
ated with asthma remission phenotypes in nasal brushes. 
In the nasal dataset, two differentially methylated regions 
were previously observed in another DNA methylation 
study of asthma remission using bronchial biopsies. This 
is the first epigenome-wide association study of asthma 
remission in both whole blood and nasal epithelial cells. 
This study is important since understanding asthma 
remission may provide new leads for future asthma treat-
ments, and epigenetic studies may help to reveal these 
cellular mechanisms.
The two replicated CpG sites were annotated to genes 
which were not known to be involved in asthma (remis-
sion) before. ClinR-associated CpG cg13378519 was 
located in the promoter region of PEX11B gene. PEX11B 
encodes a protein of the PEX11 family [22]. Overex-
pression of the PEX11B gene in human cells induces 
peroxisome proliferation [23, 24]. Our results could 
indicate a possible role of peroxisomal proliferation as 
being involved in asthma remission. ComR-associated 
CpG cg24788483 was located in the TCF7L2 gene and 
also correlated with the expression level of this gene. 
The TCF7L2 gene product is a transcription factor 
that plays a role in the Wnt signaling pathway. SNPs in 
TCF7L2 were previously reported to be strongly asso-
ciated with type-2 diabetes and this gene plays a role in 
the pancreatic insulin secretory response to incretins 
[25, 26]. Previously, the risk of asthma was reported to 
be higher in type 2 diabetes patients [27] and it has been 
suggested that treatment targeting insulin resistance may 
have a positive effect on asthma patients [28]. However, 
it has never been studied whether this treatment could 
contribute to asthma remission. In addition, we could 
not infer from the current results of association analysis 
whether the DNA methylation signal we identified is the 
cause or consequence of asthma remission.
Although remission subjects do not have asthma 
symptoms any more, they still may be different from 
healthy people. Airway abnormalities such as basement 
membrane thickening still exist in clinical and complete 
remission subjects [29]. Vermeulen et  al. [10] reported 
that the DNA methylation profile in remission subjects is 
different from that in healthy subjects. Our data in whole 
blood for our significantly replicated CpG confirmed this 
observation. The methylation levels of the ClinR associ-
ated CpG (cg13378519) were different between ClinR 
and healthy subjects, which indicated that the methyla-
tion status of subjects with asthma remission may not 
simply return to that of healthy people.
DNA methylation is cell-type specific. Both of the stud-
ied cells or tissues are highly heterogeneous and this may 
confound the association between DNA methylation 
and disease. Thus, we applied the widely used House-
man’s cell type correction method in blood samples, and 
for nasal brushes, we used SVA which showed good per-





















































(a) cg13378519 in blood (discovery) (b)  cg13378519 in nasal brush (discovery) (c)  cg13378519 in blood (Lifelines)
Fig. 3 Boxplot illustrating DNA methylation levels of cg13378519 in persistent asthma, clinical remission and complete remission subjects. a DNA 
methylation levels in whole blood in discovery cohort; b DNA methylation levels in nasal brushes in discovery cohort; c DNA methylation levels in 
whole blood in replication cohort (Lifelines)
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lacking [30]. DNA methylation is also tissue specific. 
It is yet unknown if mechanisms of remission include 
local, tissue specific airway (epithelial) effects, immune 
cell effects, or both. Matched data from whole blood and 
nasal brush samples enable us to compare DNA meth-
ylation profiles associated with asthma remission in two 
different tissues, as proxies of both immunological and 
airway specific mechanisms. Although we identified sev-
eral interesting CpG sites related to remission in nasal 
epithelium, our results of nasal brushes still need further 
replication. In previous studies, several DNA methylation 
sites were significantly associated with asthma in both 
whole blood and nasal cells [9, 31]. In our study, although 
no significant enriched cross-tissue effect of DNA meth-
ylation in asthma remission was shown, we did identify 
nine CpG sites in blood DNA that could be replicated in 
DNA of nasal brushed cells. This indicated that there may 
be shared DNA methylation signals in blood and nasal 
cells. We interpret these findings as either indicative of 
the presence of cross-tissue epigenetic mechanisms in 
blood and epithelial cells, or the possibility that the DNA 
methylation signal in nasal brushed cells is partly driven 
by immune cells in the nose [20], that are also present in 
blood.
DNA methylation might be related to the regulation of 
gene expression, and eQTM analysis may help to under-
stand the function of CpG sites. Among the eQTM genes 
that correlated with ClinR-associated CpG sites in whole 
blood, the protein encoded by PRKCH (Protein Kinase 
C Eta) plays a key role in epithelial tight junction regu-
lation which is important in maintaining the integrity 
and function of the airway epithelial barrier [32]; PDE1B 
(Phosphodiesterase 1B) encoded a protein belonging 
to phosphodiesterases (PDEs) family, and various PDE 
inhibitors showed anti-inflammatory, anti-remodelling 
and bronchodilator effect and are potential treatment of 
asthma [33]. In whole blood, 99 eQTM genes that were 
associated with ComR were enriched in eight path-
ways, among which three pathways were related to air-
way epithelial function: activation of SMO (Smoothen), 
cilium assembly and focal adhesion. The activation of 
SMO activity in bronchial epithelia enhanced the aller-
gen-induced goblet cell metaplasia, which is defined 
as a reversible transformation of airway epithelial cells 
to mucous cells such as goblet cells and may occur in 
asthma [34]. Airway cilia are important for clearance 
of inhaled particles and pathogens. One study showed 
asthma patients had less ciliated cells in airway samples 
than healthy people [35], and changes in ciliary function 
may be relevant for the development of asthma in chil-
dren [36]. Focal adhesion between the cell membrane 
and matrix are essential elements of airway smooth mus-
cle cells migration which may play an important role 
during the airway remodeling of persistent asthma [37]. 
Blood is considered as an easily accessible surrogate tis-
sue for asthma study, and previous studies showed some 
shared gene expression pattern and pathways between 
blood and airway/ lung [38, 39]. Our results suggest that 
genes related to asthma remission associated CpG sites 
may reflect a role for airway epithelial barrier and airway 
remodeling in asthma remission.
Corticosteroids treatment is usually used to control 
inflammation and improve control of asthma. One pre-
vious study identified differences in DNA methylation 
of CpG sites in blood associated with systemic corticos-
teroid treatment in patients with COPD, suggesting the 
potential effect of corticosteroids on the DNA meth-
ylation profile [40]. In our study, we therefore assessed 
the effect of ICS on the methylation levels of the two 
replicated CpG sites and found that the results were 
not affected by ICS usage. However, the effect of corti-
costeroid treatment on DNA methylation in nasal and 
blood samples of patients with asthma and remission is 
largely unknown and should be further investigated in 
the future.
Rhinitis and asthma often co-exist and show shared 
genetic origins [41]. A previous study of our group also 
showed a shared DNA methylation signal of asthma and 
rhinitis, suggesting the importance of considering the 
presence of rhinitis when doing EWAS of asthma in nasal 
epithelium [20]. In this study, we showed that additional 
adjustment for rhinitis changed the results on one of the 
replicated CpG sites (cg24788483) identified from blood. 
This remission associated CpG site was associated with 
active rhinitis in the absence of asthma, suggesting that 
blood DNA methylation profiles of persistent asthma and 
rhinitis overlap. This indicates that we should control for 
allergic rhinitis in future studies of asthma remission.
When comparing our results with those of Vermeulen 
et  al. [10] in bronchial biopsies, one CpG (cg13525448) 
in their top list of remission vs persistent asthma reached 
nominal significance (P < 0.05) in our data and showed 
the same direction in our results of ComR in whole blood 
(Additional file  2: Table  S16). This CpG site is anno-
tated to LBX1 gene and TLX1 gene by position. Besides, 
among their DMRs associated with ClinR, regions at the 
gene PTCHD3 and LOC100507389 also showed up in our 
results of ClinR in nasal brushes. SNPs in PTCHD3 gene 
were previously associated with asthma in African Amer-
ican children [42].
There are strengths and limitations in this study. 
To the best of our knowledge, this is the only cohort 
worldwide to study asthma remission in nasal brushes, 
which enable us to compare the DNA methylation pro-
file in relation to asthma remission in whole blood and 
nasal epithelium. However, because of the uniqueness 
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of this data, we could not replicate our results in nasal 
brushes in another independent cohort. Notably, we had 
matched DNA methylation and gene expression data in 
nasal brushes, which help us to get a better understand-
ing of the function of CpG sites associated with asthma 
remission in nasal brushes. Regarding the limitations 
of this study, firstly, this study was performed in a rela-
tively small sample with limited number of ComR cases, 
and the results were replicated in EGEA which is also 
with few ComR cases, which lead to low power of rep-
lication of ComR results. Secondly, although we studied 
over 450,000 DNA methylation sites, this only repre-
sents 1.6% of the human DNA methylome. Thirdly, we 
studied mixed contributions of cells in whole blood and 
nasal brushes; and although we corrected for cell types 
using established methods, potentially stronger results 
may be anticipated when studying pure cell types, as was 
previously shown for DNA methylation sites associated 
with asthma in purified blood eosinophils [8]. Finally, 
we used a cross sectional analysis at follow up to inves-
tigate asthma remission. Future studies, with prospective 
designs, should be performed to investigate if these DNA 
methylation sites can predict future asthma remission.
In conclusion, we identified replicable DNA methyla-
tion signals associated with clinical and complete asthma 
remission, which may play a role in peroxisome prolifera-
tion and Wnt signaling pathway. This could help in iden-
tifying the underlying mechanisms of asthma remission 
and also of the chronicity of the disease.
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